For much of the last year I looked forward to taking Tremfya (guselkumab) to treat my severe chronic psoriasis. My dermatologist suggested I hold off on the new IL-17A inhibitors until it was FDA approved. Now almost three months into the new treatment I am asking a question I hoped not to need to ask: what’s next?
HealtheVoices is an incredible conference for online health advocates. I've been blessed to participate in the conference for all three years, serving on the advisory panel last year. This year I went wondering what I might learn this time around. What I gained surprised me.